Compare Nuwellis Inc (NUWE) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Victoria's Secret & Co — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Victoria's Secret & Co trades at $87.3 (market cap $6.91B). The key difference: Victoria's Secret & Co is far larger — about 3140.9× Nuwellis Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Victoria's Secret & Co for 34 Days on average.
| NUWE | VSXY | |
|---|---|---|
Market Cap | $2.20M | $6.91B |
Volume | 121,544 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $99.97 |
52-Week Low | $0.68 | $28.25 |
Typical Hold Time | 26 Days | 34 Days |
Enterprise Value | -$1.52M | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Victoria's Secret (VSXY) trades at $85.79, up 0.83% today, with a bullish technical trend and strong analyst support. Recent earnings beats and a 60% buy rating from analysts highlight improving fundamentals, while the stock shows robust profitability with a 45.27% ROE. The company's 2026 revenue guidance raise and global expansion efforts signal positive momentum, though valuation remains elevated with a P/E of 19.15.
The outlook for VSXY is positive, driven by earnings growth and brand revitalization, but risks include rich valuation and competitive pressures. Upside to the $86.80 consensus target appears achievable if execution continues, yet investors face margin volatility and macroeconomic sensitivity in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
